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Abstract
Background: Genetic markers conferring susceptibility to diabetes specific renal disease remains
to be identified for early prediction and development of effective drugs and therapies. Inconsistent
results obtained from analysis of genes from classical pathways generate need for examination of
unconventional genetic markers having role in regulation of renal function. Experimental and clinical
evidences suggest that dopamine is an important natriuretic hormone. Therefore, various genes
involved in regulation of dopamine bioavailability could play a role in diabetic chronic renal
insufficiency (CRI). We investigated the contribution of 12 polymorphisms from five Dopaminergic
pathway genes to CRI among type-2 diabetic Asian Indian subjects.
Methods: Genetic association of 12 polymorphisms (SNPs) from five genes namely-dopamine
receptor-1 (DRD1), DRD2, DRD3, DRD4, andcatechol-O-methyltransferase (COMT) with diabetic
CRI was investigated using a case-control approach. Logistic regression analysis was carried out to
correlate various clinical parameters with genotypes, and to study pair wise interactions between
SNPs of different genes.
Results: SNPs -141 ins/del C and G>A (1 kb upstream from exon 2) in DRD2 gene showed
significant allelic and genotypic association. Allele -141 insC and genotype -141 insC/insC of -141 ins/
del C polymorphism, and allele A of G>A SNP were found to be predisposing to CRI. Our result of
allelic and genotypic association of -141 insC/delC SNP was also reflected in the haplotypic
association. Heterozygous genotype of polymorphism 900 ins/del C in COMT gene was predisposing
towards CRI.
Conclusion: Some polymorphisms in DRD2 and COMT genes are significantly associated with
susceptibility to CRI in the Asian Indian population which, if confirmed would be consistent with a
suggested role of dopamine metabolism in disease occurrence.
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Background
A large number of genetic association studies for
unraveling the genetic basis of renal disease in diabetes
have been carried out using polymorphisms in candidate
genes from various postulated biochemical and metabolic
pathways. These include renin-angiotensin-aldosterone
system (RAAS), protein kinase C (PKC)-polyol, advanced
glycation end (AGE) product, hexosamine and oxidative
stress. However the results are confusing and identifica-
tion of genetic susceptibility to chronic renal insufficiency
(CRI) continues to be a challenge. This suggests the need
for examining other unconventional genetic markers hav-
ing role in regulation of normal physiological functions of
kidney, especially under hyperglycemic condition.
Dopamine is an important natriuretic hormone involved
in the regulation of blood pressure, and salt-water reab-
sorption in kidney. While angiotensin II, another hor-
mone involved in natriuresis, stimulates sodium
reabsorption through activation of Na-K-ATPase and Na/
H exchanger, dopamine acts antagonistically and inhibits
reabsorption by inhibiting Na-K-ATPase and Na/H
exchanger, regulating sodium transport and excretion in
the proximal tubule [1-3]. Moreover, there are ample
empirical evidences to support that dopamine through
specific dopamine receptors influences various compo-
nents of renin angiotensin aldosterone system (RAAS).
While D1 like receptors stimulate renin release, D3 recep-
tor inhibits it [4]. D3 receptor of dopamine decreases
angiotensin II type 1 receptor (AT1) expression and angi-
otensin II binding to AT1 in renal proximal tubules [3,4].
Disruption of D3 receptor gene in mice induces a renin
dependent form of hypertension [5]. Such interactions
between dopamine and components of RAAS could mod-
ulate the potential effects of RAAS, which besides regulat-
ing vascular tone and Na ion balance in kidney also
influences cytokine mediated inflammatory pathway in
diabetic kidney disease [6-9]. In addition, administration
of nitecapone, an inhibitor of dopamine metabolizing
enzyme catechol-O-methyltransferase (COMT; EC
2.1.1.6), has been found to effectively abolish glomerular
hypertension and reduce progression to glomerulosclero-
sis by inhibiting Na-K-ATPase in a dopamine dependent
fashion [10,11]. These findings reiterate a potential role of
dopaminergic pathway genes in conferring susceptibility
to diabetic CRI through modulation of dopamine levels.
Several polymorphisms in dopaminergic pathway genes
have been identified and extensively investigated for their
role in hypertension and schizophrenia [12-17]. There is
only one report on association of D3 receptor of
dopamine with diabetic nephropathy but in individuals
with type-1 diabetes [18]. Due to significant role of genes
from dopaminergic pathway in kidney function, in this
pilot study, we investigated the susceptibility conferred by
polymorphisms in dopaminergic pathway genes to CRI




Complete clinical and demographic characteristics of the
study population have been previously reported [19].
Briefly, in this retrospective case-control analysis consecu-
tive subjects suffering from type-2 diabetes with CRI
(cases, CRI, n = 196), and diabetics without any evidence
of diabetic kidney disease (controls, DM, n = 225) were
recruited from the outpatient departments of the four par-
ticipating medical institutions situated across India. The
study was approved by respective institutional ethics com-
mittee and an informed consent obtained from all the
participants. For CRI, the inclusion criteria were subjects
with type 2 diabetes for ≥2 years, plus two or more of the
following: serum creatinine ≥150 umol/l, urinary albu-
min excretion rate (UAER) > 200 mg/l, and presence of
retinopathy. Retinopathy was diagnosed by either fundo-
scopic examination or fluoroangiographic study. 10 ml
venous blood was collected from each individual
included in the study for biochemical and genetic analy-
sis. Biochemical analyses to determine fasting glucose,
glycated hemoglobin, serum creatinine, triglycerides, total
cholesterol, and albumin were carried out at the respective
centres using automated analyzers. Using serum creati-
nine as a surrogate marker we calculated glomerular filtra-
tion rate (GFR) by using the online modified diet in renal
disease (MDRD) calculator. Patients with drug induced
nephrotoxic damage or secondary causes of albuminuria
such as obstructive renal disease, renal stone disease and
acute urinary tract infection were excluded from this
group. Normoalbuminuric (AER < 20 mg/l) type-2 diabe-
tes subjects of ≥ 10 years duration of diabetes (mean dura-
tion 17.07 ± 6.69 years) were recruited as control diabetes
subjects. Normoalbuminuria among control (DM) sub-
jects was determined by timed urine collections. An aliq-
uot of blood from the four centres was transported to the
genetics laboratory for DNA isolation. DNA was isolated
from the lymphocytes using the conventional phenol-
chloroform organic extraction method and used for
genetic analysis.
Genetic analysis
A total of 12 polymorphisms from five candidate genes
were genotyped in DM (controls) and CRI (cases) sub-
jects. These include:
COMT (+116790; 22q11.21): -287 A>G in promoter [14];
408 C>G) [20]and 472 G>A (Val 158 Met) [14] in exon 4
and 900 ins/del C in 3'UTR [15];BMC Genetics 2008, 9:26 http://www.biomedcentral.com/1471-2156/9/26
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DRD1 (*126449; 5q35.2): -48 A>G (5'UTR of exon 2)
(rs4532) [2];
DRD2 (*126450; 11q23.2): -141 ins/del C (rs1799732);
G>A, 1 kb upstream from exon 2 (rs17294542) [21,22]; and
T>C, 10 kb downstream from exon 8 (rs1800497) [21,22];
DRD3  (*126451; 3q13.31): -rs6280 C>T (ser9Gly) in
exon 2 [16];
DRD4 (*126452; 11p15.5): -120 bp duplication, 1.2 kb
upstream from initiation codon [23], -521 C>T [17]; and
48 bp VNTR in exon 3 [24].
Genotyping was done using either polymerase chain reac-
tion (PCR)-restriction fragment length polymorphisms
(RFLP) or PCR-length polymorphism (LP) approach fol-
lowing the method described in the respective quoted ref-
erences. Genotypic profiles obtained for each of the
polymorphisms are presented in Additional file 1. The
digested PCR products were resolved on 2–3% agarose gel
stained with ethidium bromide.
Statistical Analysis
Comparison of all clinical variables between DM and CRI
subjects were carried out by χ2 test for nominal variables
or t-test for continuous variables. Continuous variables
where skewed distribution was observed were compared
by Mann Whitney U test and values are reported as mean
and range. Hardy-Weinberg equilibrium (HWE) was
tested for each of the genetic marker. Allelic and genotypic
associations of SNPs/VNTRs were evaluated by Pearson's
χ2 test followed by odds ratio and 95% CI computation.
Power of the sample size for each of the SNPs was calcu-
lated using PAWE software version 1.2 [25,26]. Haplotype
analysis was performed using PHASE-standard analysis
version 2.0.2 [27,28]. Chi-square values were derived
from a series of 2 × 2 contingency tables based on the fre-
quency of each haplotype versus all others between the
DM and the CRI groups. Linear and logistic regression
analyses were carried out to correlate various clinical
parameters with genotypes and to study pair wise interac-
tions between SNPs of different genes. P values < 0.05
were subject to Bonferroni's correction.
Results
Clinical analysis
Clinical characteristics of the two patient groups are pre-
sented in Table 1.
Genetic analysis: Efficiency of PCR based genotyping was 
approximately 98% with at least two additional attempts 
for genotyping of failed samples
COMT
No allelic association of any of the four SNPs in this gene
with diabetic CRI was observed (Table 2). Only the heter-
ozygote genotype of 900 ins/del C SNP was significantly
associated with CRI (P = 0.018, OR 1.66, 95%CI 1.09–
2.52). Haplotypes generated using genotypic profiles of
the four SNPs in COMT gene are presented in Table 3. We
observed significant association of three haplotypes in
COMT gene, which were retained even after Bonferroni's
correction.
DRD1
No allelic or genotypic association of the -48 A>G poly-
morphism with CRI in our sample set was seen (Table 2).
DRD2
Of the three polymorphisms analysed in this gene, we
observed a highly significant allelic and genotypic associ-
ation of -141 ins/del C and G>A (1 kb upstream from exon
Table 1: Clinical characteristics of the study population
Characteristics DMa (n = 225) CRIb (n = 196) P
Gender (M/F) 76/149 65/131 0.89d
Age (years) 60.6 ± 11.5 57 ± 12.8 0.10c
BMI (kg/m2) 23.1 ± 0.3 23.4 ± 0.2 0.00
Duration of Diabetes (years) 17.07 ± 6.69 10.4 ± 7.7 <0.05c
Hb A1c (%) 7.3 ± 1.0 7.5 ± 1.1 0.949c
Systolic pressure (mm Hg) * 140 (106–190) 150 (110–210) 0.002e
Diastolic pressure (mm Hg) * 84 (80–104) 90 (70–110) 0.025e
Serum creatinine (µmol/l) * 84 (35–108) 177 (124–1112) <<0.05e
UAER (mg/liter)* 10 (1–16) 864 (320–1584) <<0.05e
GFR (mls/min/1.73 m2) 81.44 ± 21.85 27.83 ± 24 <<0.05c
Serum triglyceride (mmol/l) 1.7 ± 0.67 1.8 ± 1.4 0.307c
Serum cholesterol (mmol/l) 4.8 ± 0.97 4.9 ± 0.92 0.852c
Retinopathy (%) Non-proliferative (%) Proliferative (%) 24 15 09 88 35 53 <<0.05d
Cardiovascular events (%) 3 8.3
Data presented as mean ± SD (* median and range). atype-2 diabetes subjects without nephropathy (DM); b with diabetic renal insufficiency (CRI); c 
Student's t test; d Pearson's χ2 test; e Mann-Whitney U test.BMC Genetics 2008, 9:26 http://www.biomedcentral.com/1471-2156/9/26
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2) SNPs. T>C (10 kb downstream from exon 8) SNP did
not show any allelic or genotypic association with dia-
betic kidney disease (Table 2). Out of the eight possible
haplotypes in our sample set, three (-141 insC-A-T, -141
insC-A-C, and -141 delC-A-C) were significantly associ-
ated with CRI (Table 4).
DRD3
No allelic or genotypic association of the most commonly
investigated Ser9Gly SNP with CRI was observed in this
study (Table 2).
DRD4
None of the three polymorphisms tested in the gene
showed significant genotypic or allelic association with
CRI. Out of 21 possible haplotypes in our case-control
population, only haplotype 2-1-3 [(-120) no duplication
– (-521) C – VNTR 467] was found to be marginally asso-
ciated with CRI. However, after Bonferroni's correction
the haplotype did not retain significance (Additional file
2).
Table 2: Allele and genotype frequencies of SNPs in COMT, DRD1, DRD2, DRD3 and DRD4 genes and their association status with 
diabetic CRI.
SNPs Allele frequency Genotype frequency Association
DM (n = 225) CRI (n = 196) DM (n = 225) CRI (n = 196) Allele (df = 1) Genotype (df = 2)
COMT -287 G>A G = 0.63 G = 0.65 GG = 0.38 GG = 0.43 χ2 = 0.45; χ2 = 0.93;
A = 0.37 A = 0.35 GA = 0.49 GA = 0.44 P = 0.50 P = 0.63
AA = 0.13 AA = 0.13
COMT 408 C>G C = 0.71 C = 0.69 CC = 0.51 CC = 0.47 χ2 = 0.61; χ2 = 0.98;
G = 0.29 G = 0.31 CG = 0.39 CG = 0.44 P = 0.43 P = 0.61
GG = 0.10 GG = 0.09
COMT 472 G > A (Val158 Met) G = 0.53 G = 0.59 GG = 0.28 GG = 0.38 χ2 = 2.71; χ2 = 4.10;
A = 0.47 A = 0.41 GA = 0.51 GA = 0.42 P = 0.10 P = 0.13
AA = 0.21 AA = 0.20
COMT 900 Ins/Del C Ins = 0.71 Ins = 0.69 Ins/Ins = 0.54 Ins/Ins = 0.46 χ2 = 0.59; χ2 = 5.83;
Del = 0.29 Del = 0.31 Ins/Del = 0.34 Ins/Del = 0.46 P = 0.44 P = 0.054
Del/Del = 0.12 Del/Del = 0.08
DRD1 -48A>G A = 0.55 A = 0.82 AA = 0.33 AA = 0.34 χ2 = 0.33; χ2 = 1.83;
G = 0.45 G = 0.18 AG = 0.44 AG = 0.46 P = 0.57 P = 0.401
GG = 0.23 GG = 0.20
DRD2 -141 ins/del C Ins = 0.74 Ins = 0.85 Ins/Ins = 0.57 Ins/Ins = 0.74 χ2 = 12.11; χ2 = 11.3;
Del = 0.26 Del = 0.15 Ins/Del = 0.35 Ins/Del = 0.23 P < 0.001a P = 0.004a
Del/Del = 0.08 Del/Del = 0.03
DRD2 G>A G = 0.77 G = 0.66 GG = 0.61 GG = 0.45 χ2 = 7.94; χ2 = 7.83;
A = 0.23 A = 0.34 GA = 0.31 GA = 0.42 P = 0.005 P = 0.02
AA = 0.08 AA = 0.13
DRD2 T>C T = 0.74 T = 0.69 TT = 0.55 TT = 0.48 χ2 = 2.30; χ2 = 2.18;
C = 0.26 C = 0.31 TC = 0.37 TC = 0.41 P = 0.13 P = 0.335
CC = 0.08 CC = 0.11
DRD3 Ser9Gly C = 0.64 C = 0.59 CC = 0.43 CC = 0.35 χ2 = 2.03; χ2 = 2.8
G = 0.36 G = 0.41 CG = 0.42 CG = 0.48 P = 0.15 P = 0.25
GG = 0.15 GG = 0.17
DRD4 -120 bp Deletion Ins = 0.68 Ins = 0.73 Ins/Ins = 0.48 Ins/Ins = 0.53 χ2 = 1.77; χ2 = 1.72;
Del = 0.32 Del = 0.27 Ins/Del = 0.42 Ins/Del = 0.39 P = 0.18 P = 0.42
Del/Del = 0.105 Del/Del = 0.08
DRD4 -521 C>T C = 0.40 C = 0.45 CC = 0.18 CC = 0.22 χ2 = 1.25; χ2 = 1.15;
T = 0.60 T = 0.55 CT = 0.44 CT = 0.45 P = 0.26 P = 0.56
TT = 0.38 TT = 0.33
DRD4 48 bp VNTR 371 = 0.06 371 = 0.08 371/371 = 0.005 371/371 = 0.02 χ2 = 7.25; χ2 = 10.6;
419 = 0.02 419 = 0.02 467/371 = 0.10 467/371 = 0.10 P = 0.30 (df = 6) P = 0.156 (df = 7)
467 = 0.86 467 = 0.80 467/419 = 0.02 467/419 = 0.04
563 = 0.03 563 = 0.04 467/467 = 0.78 467/467 = 0.68
611 = 0.01 611 = 0.01 467/563 = 0.02 467/563 = 0.03
647 = 0.02 647 = 0.04 467/611 = 0.02 467/611 = 0.03
467/647 = 0.02 467/647 = 0.067
563/563 = 0.014 419/647 = 0.007
aSignificant after Bonferroni's correction α = 0.0042BMC Genetics 2008, 9:26 http://www.biomedcentral.com/1471-2156/9/26
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Multivariate logistic regression analysis was carried out
using disease status as a dependent variable, and age, gen-
der, BMI, duration of diabetes, creatinine clearance rate
and genotypes of all 12 polymorphisms as independent
variables. A significant association of SNPs -141 ins/del C
(P = 0.000; OR 2.85, 95%CI 1.73–4.74) and G>A (1 kb
upstream from exon 2) (P = 0.006; OR 1.84, 95%CI 1.19–
2.84) in DRD2 gene with CRI was observed. Further cate-
gorical analysis identified genotypes -141 ins/ins C (P =
0.015; OR 3.35, 95%CI 1.27–8.84) and AA (P = 0.013; OR
1.88, 95%CI 1.14–3.10) of SNPs -141 ins/del C, and G>A
(1 kb upstream from exon 2) respectively of DRD2 gene
to be predisposing to CRI. Pair-wise interactions between
different polymorphisms included in this study were
tested using multiple logistic regression analysis. No sig-
nificant interaction between any of these polymorphisms/
genes was observed.
Discussion
In addition to its classical role as a neurotransmitter,
dopamine also acts as a natriuretic hormone that has
implications in kidney function. Dopamine down regula-
tion causes Na retention and renal tissue injury [11]. In
addition dopamine also modulates the activity and avail-
ability of Ang II, the key molecule of renin-angiotensin-
aldosterone system in kidney. An altered interplay of
dopamine and Ang II could disturb the vascular tone,
sodium ion balance, and enhance cytokine-mediated
injury to renal tissue. Thus, as mentioned earlier, genetic
variations in genes controlling the bio-availability of
dopamine could be pathological. While various studies
have implicated genetic variations in COMT and
dopamine receptor genes in essential hypertension [29-
35], and one study has implicated COMT (based on a
functional assay using a COMT inhibitor) in diabetic kid-
ney disease in rats [10], an association of dopaminergic
pathway gene polymorphisms with kidney disease among
Table 3: SNP haplotypes in COMT gene
aHaplotype DM (393) n*;f** CRI (372) n*;f** χ2 P OR (95% CI)
1111 50 (0.127) 64 (0.172) 3.18 0.074 1.44 (0.96–2.15)
1112 33 (0.084) 04 (0.01) 20.48 b< 0.001 0.12 (0.04–0.34)
1121 59 (0.150) 50 (0.134) 0.33 0.56 0.89 (0.59–1.33)
1122 03 (0.007) 28 (0.075) 22.69 b < 0.001 10.66 (3.21–35.38)
1211 39 (0.01) 43 (0.115) 0.08 0.78 1.07 (0.67–1.68)
1212 55 (0.14) 51 (0.137) 0.005 0.94 0.98 (0.65–1.48)
1221 06 (0.015) 02 (0.005)
2111 23 (0.058) 24 (0.064) 0.138 0.71 1.12 (0.62–2.02)
2112 00 (0.00) 04 (0.01)
2121 103 (0.262) 62 (0.166) 9.927 b0.0016 0.57 (0.40–0.81)
2122 13 (0.033) 20 (0.05) 2.04 0.15 1.67 (0.82–3.41)
2211 01 (0.002) 08 (0.021)
2212 06 (0.015) 05 (0.013) 0.04 0.84 0.89 (0.27–2.92)
2221 02 (0.005) 07 (0.019)
aOrder of SNPs in the COMT haplotypes: -287 A>G, 408 C>G, 472 G > A and 900 Ins/Del C
bSignificant after Bonferroni's correction α = 0.0035
*n = total number
**f = frequency
Table 4: SNP haplotypes in DRD2 gene
aHaplotype DM (398) n*;f** CRI (380) n*;f** χ2 P O.R (95% CI)
111 217 (0.545) 173 (0.046) 4.97 0.03 0.69 (0.49–0.96)
211 56 (0.14) 40 (0.105) 1.65 0.20 0.73 (0.44–1.19)
112 18 (0.045) 39 (0.102) 6.94 0.01 2.37 (1.23–4.60)
212 14 (0.035) 00 (0.00) 6.23 0.01 0.09 (0.01–0.74)
121 11 (0.027) 38 (0.1) b13.51 <<0.01 4.08 (1.83–9.11)
221 01 (0.002) 01 (0.002) 0.43 0.51 1.08 (0.08–17.32)
122 41 (0.103) 80 (0.21) b12.94 <<0.01 2.33 (1.46–3.73)
222 39 (0.098) 09 (0.023) b13.50 <<0.01 0.23 (0.10–0.54)
aOrder of SNPs in the DRD2 haplotypes: -141 ins/del C – G>A (Intron 1) – T>C (Intron 7)
bSignificant after Bonferroni's correction α = 0.0063
*n = total number
**f = frequencyBMC Genetics 2008, 9:26 http://www.biomedcentral.com/1471-2156/9/26
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individuals with type-2 diabetes has not been tested in
any population so far. This is the first report on the role of
multiple SNPs in dopaminergic pathway genes conferring
susceptibility to diabetic CRI.
Out of four SNPs tested in COMT gene only 900 ins/del C
showed a strong trend towards genotypic association
(Table 2), with insC/delC  genotype being predisposing
(OR 1.66, CI 1.09–2.52) towards CRI. However, in the
absence of any evidence for the functional status of this
polymorphism at present, it would be difficult to substan-
tiate its role in CRI. Val158Met polymorphism has been
the most widely implicated for the activity status of
COMT. Presence of methionine instead of valine in the
protein makes it heat-labile and leads to fourfold reduc-
tion in activity [36]. In addition, different studies indicate
that this functional polymorphism accounts for most of
the variation in peripheral COMT activity [37]. Though,
there was no allelic or genotypic association of this SNP
(Table 2) in our study, in haplotypic combinations this
polymorphism seems to be important. Haplotype 1-1-2-2
[A-C-A (Met)-del C] is predisposing and haplotype 1-1-1-
2 [A-C-A (Val)-del C], with only one allele different at
Val158Met locus, is protective to CRI. 158Val, the high
activity allele of the enzyme, is the predominant allele in
our population and is required for regulating normal
physiological levels of dopamine. Replacement of Val
allele by Met in the haplotype may increase dopamine lev-
els, which is an antagonist to Ang II, and may alter vascu-
lar tone and sodium ion balance in kidney. The only other
significantly associated haplotype in COMT gene, 2-1-2-1
(G-C-A-InsC), is protective towards CRI (Table 3). In the
absence of any information on functional status of the
other three polymorphisms in this gene, it seems difficult
to assess the protective nature of this haplotype.
Out of eight polymorphisms in four dopamine receptor
genes (D1–D4), only SNPs -141 ins/del C and G>A (1 kb
upstream from exon 2) in DRD2 gene, showed significant
allelic and genotypic association (Table 2), with satisfac-
tory power of the sample size [G = 53% for -141 ins/del C;
G = 50.6% for G>A (1 kb upstream from exon 2)]. Odds
ratio calculation identified -141 insC allele (OR 2.01, CI
1.35–3.00) and insC/insC genotype (OR 2.19, CI 1.37–
3.50) to be predisposing, and insC/delC genotype (OR
0.53, CI 0.33–0.87) of -141 ins/del C SNP to be protective
to diabetic CRI. Allele 'A' (OR 1.68, CI 1.17–2.42) was
found to be predisposing and allele 'G' (OR 0.59, CI 0.41–
0.85), and genotype 'GG' (OR 0.52, CI 0.32–0.82) of G>A
(1 kb upstream from exon 2) SNP to be protective to CRI.
Our result of allelic and genotypic association of -141
insC/del C SNP was also reflected in the haplotypic results.
The predisposing haplotypes, 1-2-1 (-141 insC-A-T) and
1-2-2 (-141 insC-A-C), contained -141 insC allele and the
protective haplotype, 2-2-2 (-141 delC-A-C) contained
the -141 delC allele (Table 4). Based on functional analy-
sis it has been reported that -141 delC allele has decreased
promoter strength as compared to the -141 ins C allele
[38]. Considering the above mentioned facts, it could be
argued that -141 ins C allele may lead to excess bio-avail-
ability of dopamine, which may alter vascular tone and
sodium ion balance in kidney. Function of G>A SNP (I Kb
upstream from exon 2) in the gene is not known and thus
it's difficult to comment on our observation on this SNP.
There are a few study limitations. Present study is a candi-
date gene based case-control study and most candidate
gene case-control studies of complex traits to date have
been disappointing. In diabetic nephropathy alone, many
initial reports of significant associations have not with-
stood the test of replication in other cohorts. Such incon-
sistencies stem primarily from the very low pre-test
probability that any given gene contributes to the suscep-
tibility of a complex trait despite apriori hypotheses based
on cell, tissue, or animal model experiments. Other rea-
sons include the use of underpowered sample sizes, mul-
tiple testing, phenotypic heterogeneity, poor phenotype
characterization, selection bias, population stratification,
and incomplete knowledge of the complete set of allelic
variants in the region of a candidate gene. Our study
involves a small sample size. Harrington has commented
on standards of evidence in the genomic age and suggests
that in a case control study the sample size should be
>1000 subjects to arrive at worthwhile conclusions [39].
However, only a very few investigators have access to such
a large data and inspite of being a multi-site study the
present study could not achieve such large numbers. On
the other hand the present study fulfils most of the criteria
of a good genetic association study suggested by Hatters-
ley et al [40]. The diagnosis of diabetic renal disease in the
present study is based on multiple criteria. Diabetes can
produce a large variety of renal lesions and it is likely that
molecular and genetic pathways involved in each of these
are different. This is the first investigation of association of
polymorphisms in the dopaminergic pathway genes with
CRI. Significant allelic, genotypic, and haplotypic associa-
tions observed with diabetic CRI in this study seem inter-
esting but extrapolation of the results demands
replication in a larger sample set.
Conclusion
It is concluded that polymorphisms -141 ins/del C and
G>A (1 kb upstream from exon 2) in DRD2, and 900 ins/
del C in COMT genes are associated with susceptibility to
diabetic CRI, which if confirmed by replication studies
and/or expression analysis would be consistent with a role
of dopamine metabolism in disease occurrence. Given
that some of the genetic variants were associated with sus-
ceptibility and others with protection could be an impor-
tant indication of the mechanisms of CRI itself. The use ofBMC Genetics 2008, 9:26 http://www.biomedcentral.com/1471-2156/9/26
Page 7 of 8
(page number not for citation purposes)
the apposite polymorphisms for prediction or prognosis
could well be a subordinate step to that of the confirma-
tion of the observation and of understanding the disease
itself.
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